Cancer Doctors Recoil at Experimental Change in Drug Reimbursements

The Associated Press reports that medicare’s proposal for changes to reimbursement processes for chemotherapy and other drugs administered in the office is sparking an uproar across specialist doctors, drugmakers, and some patient advocacy groups, with much of the focus placed on high-cost medications and the ongoing problem of runaway drug costs. Read the AP article posted on www.chicagotribune.com here…

 

Notice: The “Read more…” link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid  on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.